I-32

N/A

Report date: 2025/01/26 18:28:34
NME

Base Information

Drug NameI-32
Drug Alias NameATP-citrate lyase/acetyl-CoA carboxylase inhibitor (Espervita Therapeutics/McMaster University)I-32
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP-citrate synthase inhibitorsAcetyl-CoA carboxylase 1 inhibitorsAcetyl-CoA carboxylase 2 inhibitors
TargetsATP-citrate synthaseAcetyl-CoA carboxylase 1Acetyl-CoA carboxylase 2
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMcmaster University
China Registration ClassN/A

Develop Information

Active CompaniesEspervita Therapeutics IncMcmaster University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A